EcoDrugPlus

Cytochrome P450 26a1

Ensembl ID : ENSONIG00000007241
Gene Symbol: LOC100695684
4 Cross references
194 Possible Orthologues:

Cytochrome P450 3a30

Ensembl ID : ENSONIG00000001039
Gene Symbol: LOC100702592
2 Cross references
518 Possible Orthologues:

Cytochrome P450 3a30

Ensembl ID : ENSONIG00000003249
Gene Symbol: LOC100700506
4 Cross references
474 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSONIG00000008307
Gene Symbol: CYP19A1
3 Cross references
244 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSONIG00000034059
Gene Symbol: CYP3A65
1 Cross references
540 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSONIG00000037961
Gene Symbol: CYP3A65
1 Cross references
540 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSONIG00000003231
Gene Symbol: CYP3A65
1 Cross references
539 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSONIG00000035482
Gene Symbol: CYP3A65
1 Cross references
538 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSONIG00000038385
Gene Symbol: LOC100697329
4 Cross references
191 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSONIG00000041248
Gene Symbol: LOC100712161
4 Cross references
197 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSONIG00000036515
Gene Symbol: LOC100695832
3 Cross references
189 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSONIG00000039219
Gene Symbol: LOC100712332
4 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).